Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
Excellent balance sheet with high growth potential.
Share Price & News
How has Seattle Genetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SGT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how SGT performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how SGT performed against the German Market.
Price Volatility Vs. Market
How volatile is Seattle Genetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Seattle Genetics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SGT (€139) is trading below our estimate of fair value (€194.76)
Significantly Below Fair Value: SGT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SGT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SGT is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SGT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SGT is overvalued based on its PB Ratio (15.4x) compared to the DE Biotechs industry average (5x).
How is Seattle Genetics forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SGT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: SGT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SGT's is expected to become profitable in the next 3 years.
Revenue vs Market: SGT's revenue (34.3% per year) is forecast to grow faster than the German market (5.8% per year).
High Growth Revenue: SGT's revenue (34.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SGT is forecast to be unprofitable in 3 years.
How has Seattle Genetics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SGT is currently unprofitable.
Growing Profit Margin: SGT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SGT is unprofitable, and losses have increased over the past 5 years at a rate of -18.9% per year.
Accelerating Growth: Unable to compare SGT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SGT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: SGT has a negative Return on Equity (-17.77%), as it is currently unprofitable.
How is Seattle Genetics's financial position?
Financial Position Analysis
Short Term Liabilities: SGT's short term assets ($1.2B) exceed its short term liabilities ($257.2M).
Long Term Liabilities: SGT's short term assets ($1.2B) exceed its long term liabilities ($68.6M).
Debt to Equity History and Analysis
Debt Level: SGT is debt free.
Reducing Debt: SGT has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SGT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SGT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Seattle Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SGT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SGT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SGT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SGT's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Clay Siegall (58yo)
Dr. Clay B. Siegall, Ph.D. co-founded Seattle Genetics, Inc. in 1997 and has been its Chief Executive Officer since November 2002 and its President since June 2000. Dr. Siegall has nearly 20 years of exper ...
CEO Compensation Analysis
Compensation vs Market: Clay's total compensation ($USD14.52M) is above average for companies of similar size in the German market ($USD5.12M).
Compensation vs Earnings: Clay's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||14.58yrs||US$4.49m||0.065% $15.8m|
|General Counsel||5.42yrs||US$3.97m||0.013% $3.2m|
|Chief Medical Officer||2yrs||US$6.72m||0.0013% $310.9k|
|Chief Technology Officer||3.75yrs||US$3.95m||0.080% $19.5m|
|VP of Investor Relations & Executive Director of Corporate Communications||no data||no data||no data|
|Senior Vice President of Corporate Development||9yrs||no data||no data|
|Vice President of Marketing||4.42yrs||no data||no data|
|Executive Vice President of Human Resources||no data||no data||no data|
|Executive Vice President of Commercial||no data||no data||0.0090% $2.2m|
Experienced Management: SGT's management team is seasoned and experienced (5.4 years average tenure).
|Independent Director||6.33yrs||US$442.77k||0.013% $3.1m|
|Independent Director||15.17yrs||US$445.63k||0.026% $6.4m|
|Independent Director||12.83yrs||US$431.04k||0.030% $7.4m|
|Lead Independent Director||15.17yrs||US$482.74k||0.12% $28.3m|
|Independent Director||19.83yrs||US$427.60k||0.074% $18.0m|
|Independent Director||16.83yrs||US$421.31k||0.021% $5.3m|
|Independent Director||8.17yrs||US$435.63k||0.013% $3.1m|
|Independent Director||2.17yrs||US$433.04k||no data|
Experienced Board: SGT's board of directors are seasoned and experienced ( 15.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SGT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.3%.
Seattle Genetics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Seattle Genetics, Inc.
- Ticker: SGT
- Exchange: DB
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$27.213b
- Listing Market Cap: US$24.478b
- Shares outstanding: 173.10m
- Website: https://www.seattlegenetics.com
Number of Employees
- Seattle Genetics, Inc.
- 21823 30th Drive SE
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SGEN||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Mar 2001|
|SGT||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2001|
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seattle Genetics, Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and biotechnology and pharmaceutical companies. Seattle Genetics, Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/31 21:39|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.